Researchers utilized diffusion tensor imaging to track how the hybrid therapy—which pairs levodopa with personalized digital interventions—influences brain connectivity. The data indicates that patients using the platform exhibit reorganized neural pathways and more efficient communication within motor-related circuits. These structural shifts correlate directly with improved clinical outcomes, reinforcing the theory that targeted digital training promotes neuroplasticity even in progressive neurodegenerative conditions.

The findings were developed in collaboration with Reichman University, marking a shift in how clinicians approach the disease. Rather than focusing solely on dopamine deficiency, the intervention engages distributed networks spanning cognitive, sensory, and motor systems. According to Prof. Amir Amedi, Remepy's Chief Science Officer, the evidence suggests that structured, multimodal digital tools can effectively modulate these networks to complement traditional medication. With the Phase IIa data now supported by structural neuroimaging, the company is moving to validate these results in a larger, late-stage trial. Hybridopa™ remains an investigational product, currently awaiting regulatory approval.